Research and Clinical Trials

Evaluating Erlotinib and Chemoradiation as Treatment for Pancreatic Cancer
Brief Description  
This study is a randomized trial that will evaluate whether the addition of erlotinib to gemcitabine adjuvant chemotherapy improves survival as compared to gemcitabine alone following R0 or R1 resection of head of pancreas adenocarcinoma. It will also evaluate whether the use of concurrent fluoropyrimidine and radiotherapy following adjuvant gemcitabine based chemotherapy further enhances survival for such patients who are without evidence of progressive disease after 5 cycles of gemcitabine.
Who may be Eligible  

  • Histologic proof of primary head of pancreas invasive adenocarcinoma managed with a potentially curative resection (i.e., removal of all gross tumor) involving a classic pancreaticoduodenectomy (Whipple) or a pylorus preserving pancreaticoduodenectomy. Patients with invasive adenocarcinoma that also contains a component of intraductal papillary mucinous neoplasm (PIMN) are eligible
  • Interval between definitive tumor-related surgery and 1st step registration between 21-56 days.
  • Patients will be staged according to the 6th edition JCC staging system with pathologic stage T1-3, N0-1, M-0 being eligible. Pathologic reporting using the CPS format is strongly encouraged.
  • Age = 18.
  • Zubrod performance status 0 or 1.
IRB Number  
Principal Investigator  
Salmon, Stuart

For More Information, Contact  Delois  , DeShazo
Phone:  (704) 355-1342  Fax:  (704) 355-1353 704 
Address:1100 South Tryon Street Suite 220 Charlotte, NC 28203